ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Carcinoma
Colorectal Cancer
Lung Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near New York, NY, USA:

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastro...

Active, not recruiting
Pancreatic Cancer
Radiation: Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Viewray

New York, New York, United States and 12 other locations

This research study is studying a combination of interventions as a possible treatment for pancreatic tumor.The interventions involved in th...

Active, not recruiting
Pancreatic Cancer
Drug: Nivolumab
Drug: FOLFIRINOX

Phase 2

Mass General Brigham
Mass General Brigham

New York, New York, United States and 9 other locations

with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Phase 3

FibroGen
FibroGen

New York, New York, United States and 89 other locations

Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies....

Enrolling
Pancreatic Cancer
Drug: MVT-5873
Drug: gemcitabine + nab-paclitaxel

Phase 1

BioNTech
BioNTech

New York, New York, United States and 4 other locations

The purpose of this study is to find out which doses of talimogene laherparepvec (T-Vec) can be given safely to participants with pancreatic ...

Active, not recruiting
Pancreatic Cancer
Drug: Talimogene laherparepvec

Phase 1

Karie D. Runcie, MD

New York, New York, United States

study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Par...

Enrolling
Pancreatic Cancer
Drug: PBP1510 (400mg/16mL)
Drug: Gemcitabine (1000 mg/m^2)

Phase 1, Phase 2

Prestige Biopharma

New Hyde Park, New York, United States and 2 other locations

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer...

Enrolling
Pancreatic Adenocarcinoma
Metastatic
Genetic: VCN-01
Drug: Gemcitabine

Phase 2

Theriva Biologics

New York, New York, United States and 16 other locations

ONIVYDE + LV + 5-FU chemotherapy regimen in patients with advanced pancreatic cancer and to determine the recommended dose for the ...

Active, not recruiting
Pancreatic Cancer
Biological: XB2001 or Placebo

Phase 1, Phase 2

XBiotech

Bronx, New York, United States and 27 other locations

open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...

Active, not recruiting
Gastric Cancer
Pancreatic Cancer
Biological: CT041

Phase 1, Phase 2

CARsgen Therapeutics

New York, New York, United States and 15 other locations

doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic...

Enrolling
Pancreas Cancer
Biological: L-DOS47
Drug: Doxorubicin

Phase 1, Phase 2

Helix BioPharma

Morristown, New Jersey, United States and 2 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems